Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 12—December 2024
CME ACTIVITY - Research

Ophthalmic Sequelae of Ebola Virus Disease in Survivors, Sierra Leone

Charlene H. Choo, Laura Ward, Ian Crozier, Tolulope Fashina, Daisy Yan, Brent R. Hayek, Caleb Hartley, Matthew Vandy, John G. Mattia, Lloyd Harrison-Williams, Jalikatu Mustapha, Carolyn Drews-Botsch, Steven Yeh1, and Jessica Shantha1Comments to Author 
Author affiliation: University of Nebraska Medical Center, Omaha, Nebraska, USA (C.H. Choo, T. Fashina, C. Hartley, S. Yeh); Emory University, Atlanta, Georgia, USA (L. Ward, S. Yeh, J. Shantha); Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA (I. Crozier); University of California, San Francisco, California, USA (D. Yan, J. Shantha); North Georgia Eye Clinic, Gainesville, Georgia, USA (B.R. Hayek); Ministry of Health and Sanitation, Freetown, Sierra Leone (M. Vandy, J.G. Mattia, L. Harrison-Williams, J. Mustapha); George Mason University, Fairfax, Virginia, USA (C. Drews-Botsch)

Main Article

Table 4

Demographic and clinical characteristics associated with uveitis status in survivors in study of ophthalmic sequelae after Ebola virus disease, Sierra Leone*

Characteristics Total, N = 521 Uveitis, n = 69 No uveitis, n = 452 OR (95% CI) p value
Age, mean (SD), n = 496
 31.1 (16.0)
 29.7 (12.7)
 31.3 (16.5)
 0.97 (0.95–0.99)
 0.048
Sex, N = 510 1.78 (1.03–3.05)† 0.036
F 285 (55.9) 46 (16.1) 239 (83.9)
M
 236 (45.3)
 13 (9.7)
 223 (90.3)
Days in ETU, mean (SD), n = 184 26.8 (21.4) 22.7 (12.3) 27.4 (22.5) 0.99 (0.97–1.01) 0.182
Previous eye exam, n = 513 444 (86.5) 67 (15.1) 377 (84.9) 5.95 (1.42–24.88) 0.006
History of cataract, n = 510 42 (8.2) 16 (38.1) 26 (61.9) 4.82 (2.43– 9.56) <0.001
History of uveitis, n = 510 51 (10.0) 12 (17.4) 39 (8.8) 2.17 (1.07–4.39) 0.030
Vision loss symptoms, n = 510 134 (26.3) 26 (19.4) 108 (21.2) 1.86 (1.09–3.18) 0.026

*Values are no. (%) except as indicated. ETU, Ebola treatment unit; OR, odds ratio. †OR is the odds of uveitis for women vs. men.

Main Article

1These authors were co–principal investigators.

Page created: November 04, 2024
Page updated: November 22, 2024
Page reviewed: November 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external